R1 Therapeutics (private company)
See something wrong or missing? Let us know
Offices:London
Industry:BiotechHealth servicesPharma
Business model:B2B
R1 Therapeutics is a British clinical-stage biotechnology company focused on kidney disease, with a focus on developing the AP306 drug, which was licensed from Alebund Pharmaceuticals
Investors:
we tracked 3 investors
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
values in USD
Investments 77.5M
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Companies with similar profile to R1 Therapeutics
| Name | Criteria | |
|---|---|---|
![]() |
AbolerIS Pharma
67%
|
|
![]() |
Acesion Pharma
67%
|
|
![]() |
Cinclus Pharma
67%
|
|
![]() |
Citryll
67%
|
|
![]() |
Tozaro
67%
|
|
![]() |
NMD Pharma
67%
|
|
![]() |
Octarine Bio
67%
|
|
![]() |
ReViral
67%
|
|
![]() |
Sanifit Therapeutics
67%
|
|
![]() |
STipe Therapeutics
67%
|
|






Belgium
Austria
Germany
Switzerland
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Ireland
Italy
Portugal